GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Azitra Inc.
Azitra is a biotech company developing microbiome-based treatments for skin diseases. Its stock price represents a venture bet on this innovative approach to dermatology.
Share prices of companies in the market segment - Pharma skin
Azitra is a biopharmaceutical company developing skin microbiome-based treatments for dermatological conditions such as eczema. We've classified it in the "Pharma: Skin" category. The chart below shows how the market values innovative approaches in dermatology.
Broad Market Index - GURU.Markets
Azitra is a biotech company developing skin microbiome-based treatments for dermatological conditions. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
AZTR - Daily change in the company's share price Azitra Inc.
Azitra, Inc.'s daily price change reflects the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its skin treatments.
Daily change in the price of a set of shares in a market segment - Pharma skin
Azitra, Inc. is a biotech company using the skin microbiome to develop new treatments for skin diseases. This is a cutting-edge and innovative field. The chart below shows the volatility in the biotech sector, which helps assess how the market is responding to Azitra's unique approach.
Daily change in the price of a broad market stock, index - GURU.Markets
Azitra is a pharmaceutical company focused on dermatology. Its shares are driven by successful drug commercialization and clinical trial results. The dynamics of this niche healthcare segment are part of a larger and more diverse picture of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Azitra Inc.
Azitra, Inc.'s year-over-year performance is a story of microbiome-based drug development for skin conditions. Its 12-month market cap is entirely dependent on clinical trial data. The success of its approach, which leverages "good" bacteria, could offer a new, safe way to treat conditions such as eczema.
Annual dynamics of market capitalization of the market segment - Pharma skin
As an early-stage biotech, Azitra is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its skin treatments. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Azitra is a biotech company developing microbiome-based drugs. Its dynamics are completely disconnected from the market and are determined by news of the clinical successes or failures of its drugs. It's a high-risk game, where scientific data can change everything overnight.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Azitra Inc.
Azitra is a clinical-stage biotech focused on dermatology. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its lead programs is a binary outcome for its stock.
Monthly dynamics of market capitalization of the market segment - Pharma skin
Biotechnology that uses the skin microbiome to treat diseases is a new and promising approach. The dynamics of this sector, shown in the graph, reflect its early stage and research intensity. Companies like Azitra are conducting research in this innovative field.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Azitra is an early-stage biotech company. Its shares exist in a world of laboratory data and investor expectations about science. Their value can fluctuate wildly, ignoring any macroeconomic events or general market movements.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Azitra Inc.
Azitra, a biotech company using the skin microbiome to treat skin conditions, is at the forefront of science. Its weekly stock price is reflecting clinical trial data and investor confidence in the potential of this innovative approach to dermatology.
Weekly dynamics of market capitalization of the market segment - Pharma skin
Azitra is a biotech company that uses the skin microbiome to develop treatments for skin conditions. This innovative approach leverages "good" bacteria. The chart below shows how its stock performs in its own news cycle, independent of traditional dermatology.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Azitra is a biotech company using the skin microbiome for treatment. This is an innovative approach. The chart will show how its stock fares in its own news cycle, independent of traditional dermatology and the broader market.
Market capitalization of the company, segment and market as a whole
AZTR - Market capitalization of the company Azitra Inc.
Azitra's market capitalization reflects investors' bets on its developments in microbiome-based dermatology. The chart reflects the market's belief that beneficial bacteria can be used to treat skin conditions. Its low valuation reflects the scientific potential of its platform, which is in early clinical trials.
AZTR - Share of the company's market capitalization Azitra Inc. within the market segment - Pharma skin
Azitra is a biotech company developing skin microbiome-based treatments for dermatological diseases. Its market share is negligible, but it operates at the cutting edge of science. Its market cap is a bet on its platform, which harnesses "good" bacteria to combat skin diseases.
Market capitalization of the market segment - Pharma skin
This graph shows the total value of the entire pharmaceutical sector focused on skincare. For Azitra, which works with the skin microbiome, this line is a map of the future of dermatology. The graph's growth reflects how science is beginning to understand the role of bacteria in skin health, opening up entirely new approaches to treating skin conditions.
Market capitalization of all companies included in a broad market index - GURU.Markets
Azitra is a biotech company using the skin microbiome to treat dermatological conditions. Its market capitalization is determined by its innovative "good bacteria for skin" approach. This represents the market share of microbiome science.
Book value capitalization of the company, segment and market as a whole
AZTR - Book value capitalization of the company Azitra Inc.
Azitra is a biotech company developing microbiome-based treatments for skin diseases. Its book value is its scientific and financial capital. It consists of cash for R&D and its unique microbial library. How has this capital changed? The chart below shows.
AZTR - Share of the company's book capitalization Azitra Inc. within the market segment - Pharma skin
Azitra, Inc. is a biotech company developing skin microbiome-based treatments. Its research requires a dedicated laboratory for working with live bacteria and developing new therapeutic approaches. The chart shows the company's share of the R&D infrastructure for this cutting-edge field.
Market segment balance sheet capitalization - Pharma skin
Azitra is a biotechnology company. The pharmaceutical industry, as the graph shows, is both knowledge- and capital-intensive. Azitra focuses on drug development, and its capital is its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Azitra's assets are not creams, but a scientific platform for developing live biotherapeutic products based on beneficial bacteria for the treatment of skin conditions such as eczema. Its book value reflects its laboratory base for this skin microbiome research.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Azitra Inc.
Azitra is a biotech company using the skin microbiome to treat skin diseases. Its market value is a reflection of its innovative approach. Investors are betting on its ability to create a new class of "living" drugs.
Market to book capitalization ratio in a market segment - Pharma skin
Azitra is a biotech company developing microbiome-based treatments for skin diseases. Its high rank on this chart reflects its innovative approach, which could offer new treatment options.
Market to book capitalization ratio for the market as a whole
Azitra is a biotech company using the skin microbiome to treat skin diseases. This is a cutting-edge scientific approach. The company's market value reflects investor confidence in the potential of this emerging field of medicine. This chart shows the market's appetite for breakthrough, yet risky, scientific concepts.
Debts of the company, segment and market as a whole
AZTR - Company debts Azitra Inc.
Azitra, a clinical-stage biopharmaceutical company developing drugs to treat skin diseases, is entirely dependent on external funding. This chart shows the startup's financial needs during the long journey from scientific concept to approved drug.
Market segment debts - Pharma skin
Azitra is a clinical-stage biotech company developing live biotherapeutics (microbes) for the treatment of skin diseases. This innovative approach utilizes beneficial bacteria to restore skin health. The chart shows how the company funds its research in this cutting-edge field of dermatology.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Azitra Inc.
Azitra is a biotech company developing live biotherapeutics based on the skin microbiome for the treatment of skin diseases. This is a cutting-edge, but very expensive, area of research. This chart shows how the company uses debt to finance its innovative, yet high-risk, clinical programs in dermatology.
Market segment debt to market segment book capitalization - Pharma skin
Azitra is a biopharmaceutical company using the skin microbiome to develop treatments for skin diseases. It's an innovative approach. This chart shows how the company finances its unique research. It relates its debt structure to the overall financial picture in the capital-intensive biotech sector.
Debt to book value of all companies in the market
Azitra, Inc. is a biotech company developing microbiome-based treatments for skin diseases. This is a cutting-edge but capital-intensive field. How heavily is the company reliant on debt in its early stages? This graph of total debt in the economy helps assess the riskiness of its financial model.
P/E of the company, segment and market as a whole
P/E - Azitra Inc.
Azitra is a clinical-stage biopharmaceutical company developing genetically engineered bacteria to treat skin diseases. This chart shows how investors view its innovative approach, which leverages the skin microbiome.
P/E of the market segment - Pharma skin
Azitra, Inc. is a clinical-stage biopharmaceutical company developing genetically engineered bacteria to treat skin diseases using the skin microbiome. This chart illustrates the average valuation in the dermatology pharmaceutical sector, where investors are betting on breakthrough approaches based on microbiome-based therapies.
P/E of the market as a whole
Azitra, Inc. is a clinical-stage biopharmaceutical company developing live biotherapeutics based on the skin microbiome for the treatment of skin diseases. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether AZTR's valuation is based on faith in its unique scientific approach or is moving in line with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Azitra Inc.
Azitra, Inc. is a clinical-stage biopharmaceutical company developing genetically engineered bacteria to treat skin diseases. Their approach leverages the microbiome for therapeutic purposes. This chart reflects investors' confidence in this innovative approach and its potential to create a new class of drugs in dermatology.
%20P%2FE%20Azitra%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Azitra-Inc.&v=1772584892698 "Chart of the company's future (projected) P/E Azitra Inc.")
Future (projected) P/E of the market segment - Pharma skin
Azitra is a biotech company developing skin microbiome-based treatments for dermatological diseases. This represents a new approach to treatment. The chart reflects future revenue forecasts for the sector, helping to understand the level of investor confidence in this innovative scientific platform and its commercial potential.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-skin&v=1772584892743 "Future (projected) P/E graph of the market segment - Pharma skin")
Future (projected) P/E of the market as a whole
Azitra is a clinical-stage biotech company developing skin microbiome-based treatments for dermatological diseases. This represents a new approach to medicine. This biotech risk appetite chart reflects investors' willingness to fund cutting-edge scientific concepts such as microbiome engineering.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772584892759 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Azitra Inc.
Azitra, Inc. is a clinical-stage biotechnology company developing genetically engineered bacteria to treat skin diseases. This innovative approach leverages the skin microbiome. Financial metrics reflect R&D expenditures. This chart shows investments in cutting-edge science to create a new class of dermatological treatments.
Profit of companies in the market segment - Pharma skin
Azitra, Inc. is a clinical-stage biotechnology company developing skin microbiome-based treatments for dermatological conditions such as cancer-related rashes. This chart shows the overall profitability of the dermatological pharmaceutical sector, where using beneficial bacteria to restore skin health is a new and promising approach.
Overall market profit
Azitra, Inc. is a biotech company developing treatments for skin diseases using the microbiome. Its success depends on the results of clinical trials. This innovative approach is unrelated to the general economic cycles visible in this chart. The company's value lies in its scientific potential.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Azitra Inc.
Azitra is a clinical-stage biotech company using the skin microbiome to develop treatments for skin diseases. Future profits depend on the success of its innovative approach. This chart reflects analysts' speculative expectations for the future of microbiome-based dermatology.
%20profit%20of%20the%20company%20Azitra%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Azitra-Inc.&v=1772584892987 "Graph of future (projected) profit of the company Azitra Inc.")
Future (predicted) profit of companies in the market segment - Pharma skin
Azitra is a biotech company developing microbiome-based treatments for skin conditions. Its approach utilizes beneficial bacteria to restore healthy skin balance. This chart shows revenue projections for the dermatology pharmaceutical segment, providing context for evaluating Azitra's innovative science.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-skin&v=1772584893051 "Graph of future (predicted) profits of companies in a market segment - Pharma skin")
Future (predicted) profit of the market as a whole
Azitra, Inc. is a biopharmaceutical company developing microbiome-based treatments for skin diseases. Its future depends on the results of clinical trials. This economic outlook affects investors' overall risk appetite, which is critical for biotech funding.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772584893173 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Azitra Inc.
Azitra is a clinical-stage biotech company using the skin microbiome to treat skin diseases. It has no revenue. This chart reflects investors' faith in its innovative approach, which involves harnessing "good" bacteria to fight disease.
P/S market segment - Pharma skin
Azitra is a clinical-stage biotech company developing live biotherapeutics (microbes) for the treatment of skin diseases. Their approach is based on using beneficial bacteria to restore a healthy skin microbiome. This chart shows the average revenue estimate for the sector, which helps assess how the market views this innovative approach in dermatology.
P/S of the market as a whole
Azitra is a clinical-stage biotech company developing skin microbiome-based treatments for dermatological conditions such as eczema. This chart highlights that the valuation of such companies is based on their innovative scientific approach and the potential to create a new class of drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Azitra Inc.
Azitra is a clinical-stage biopharmaceutical company developing beneficial bacteria-based treatments for skin conditions such as eczema. Its revenue valuation is important to the company. It reflects investor expectations for the success of its innovative approach, which harnesses the skin's microbiome to restore skin health, and the commercial potential of its products.
%20P%2FS%20Azitra%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Azitra-Inc.&v=1772584893246 "The graph of the company's future (projected) P/S Azitra Inc.")
Future (projected) P/S of the market segment - Pharma skin
Azitra is a biotech company developing microbiome-based treatments for skin conditions. This chart compares the company's estimated future sales with industry expectations. It shows how investors view its innovative approach to harnessing beneficial bacteria to restore skin health and the potential of its developments.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20skin&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-skin&v=1772584893272 "Future (projected) P/S market segment graph - Pharma skin")
Future (projected) P/S of the market as a whole
Azitra is a biotech company developing skin microbiome-based treatments for skin conditions such as atopic dermatitis. The company's future depends on the success of this innovative approach. This market forecast chart reflects growing investor interest in microbiome-based therapies as a new frontier in medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772584893314 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Azitra Inc.
This figure reflects the financial activity of Azitra, Inc., a clinical-stage biotechnology company developing microbiome-based therapies for skin diseases. There are no commercial sales revenues, and cash flows are related to research and development expenses.
Sales of companies in the market segment - Pharma skin
Azitra, Inc. is a clinical-stage biotechnology company using the skin microbiome to develop treatments for dermatological conditions. It currently has no sales revenue. Its future revenue will depend on the success of its innovative approach to skin health.
Overall market sales
Azitra, Inc. is a clinical-stage biotechnology company developing microbiome-based treatments for skin diseases. The company offers an innovative approach to dermatology. This general economics chart does not reflect Azitra's prospects, which are determined solely by scientific breakthroughs and clinical trial results.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Azitra Inc.
Azitra, Inc. is a biopharmaceutical company developing skin microbiome-based treatments for dermatological conditions. Its approach utilizes beneficial bacteria to restore skin health. Future revenue is dependent on the success of clinical trials. The chart reflects analyst expectations for the potential of this new therapeutic modality.
%20sales%20of%20the%20company%20Azitra%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Azitra-Inc.&v=1772584893492 "Schedule of future (projected) sales of the company Azitra Inc.")
Future (projected) sales of companies in the market segment - Pharma skin
Azitra, Inc. is a biotech company using the skin microbiome to develop new treatments for dermatological diseases. This chart shows sales forecasts for the dermatology market. Is a breakthrough in microbiome therapy expected, creating a new niche? This reflects the potential of this field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-skin&v=1772584893516 "Schedule of future (projected) sales of companies in the market segment - Pharma skin")
Future (projected) sales of the market as a whole
Azitra is a biotech company specializing in the development of microbiome-based treatments for skin diseases. Its success depends on clinical trial results and scientific progress. The general economic cycles reflected in this chart are not directly related to the fundamental drivers and risks associated with this innovative approach to medicine.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772584893546 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Azitra Inc.
Azitra is a clinical-stage biotechnology company developing live biotherapeutics based on the skin microbiome for the treatment of skin diseases. This chart reflects its financial performance. Profitability is a future goal, dependent on the success of its innovative approach, which uses beneficial bacteria to restore skin health.
Market segment marginality - Pharma skin
Azitra, Inc. is a clinical-stage biotechnology company developing microbiome-based therapies for the treatment of skin diseases. This chart reflects its financial position, with profitability being a future goal dependent on the success of its innovative approach in clinical trials.
Market marginality as a whole
Azitra, Inc. is a biotech company using the skin microbiome to develop treatments for skin diseases. It operates at the forefront of dermatology. This gross margin chart reflects investor appetite for risky but potentially breakthrough research projects that require long-term funding.
Employees in the company, segment and market as a whole
Number of employees in the company Azitra Inc.
Azitra is a clinical-stage biotech company using the skin microbiome to treat dermatological conditions. Its small team of scientists is its greatest asset. This graph shows how the team is growing as its living biotherapeutic products progress through early clinical trials, a key milestone.
Share of the company's employees Azitra Inc. within the market segment - Pharma skin
Azitra is a clinical-stage biotech company developing skin microbiome-based treatments for dermatological diseases. Its team consists of microbiologists and dermatologists. This chart shows the company's market share, reflecting its scientific focus and the scale of its R&D activities in this emerging field of medicine.
Number of employees in the market segment - Pharma skin
Azitra, Inc. is a biopharmaceutical company that uses the skin microbiome to develop treatments for skin diseases. The chart shows employment in the skin pharmaceutical sector. Azitra's approach utilizes beneficial bacteria to combat diseases, representing a new direction in dermatology.
Number of employees in the market as a whole
Azitra is a biotech company developing skin microbiome-based treatments for skin diseases. It's at the forefront of dermatology. Its staff growth isn't a reflection of economics, but rather a consequence of research progress. Given the overall dynamics in this chart, Azitra represents the venture sector, where jobs are being created for innovative scientists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Azitra Inc. (AZTR)
Azitra is a biotech company using microbiome engineering to treat skin diseases. This is cutting-edge R&D. This chart shows the high speculative value the market attributes to their scientific platform. It reflects the market capitalization per scientist, which is a bet on their unique approach to dermatology.
%20of%20the%20company%20Azitra%20Inc.%20(AZTR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Azitra-Inc.-AZTR&v=1772584893791 "Chart of market capitalization per employee (in thousands of dollars) of the company Azitra Inc. (AZTR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma skin
Azitra (AZTR) is a biopharmaceutical company developing microbiome-based treatments for skin diseases. In this innovative field, this metric reflects the potential of their scientific approach. A high market capitalization per employee may indicate that investors believe in the company's ability to create "living medicines" by restoring a healthy balance of microorganisms on the skin.
%20by%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-skin&v=1772584893817 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma skin")
Market capitalization per employee (in thousands of dollars) for the overall market
Azitra is a biotech company developing skin microbiome-based treatments for dermatological conditions. Its valuation is based on a unique scientific approach. The chart shows a high valuation per employee, as the market sees great potential in using "good" bacteria to restore skin health.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772584893835 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Azitra Inc. (AZTR)
Azitra is a clinical-stage biotech company developing skin microbiome-based treatments for dermatological diseases. This chart shows the net loss per employee. It reflects that every scientist at the company represents an R&D investment, funded to test hypotheses and conduct trials.
%20Chart%20Azitra%20Inc.%20(AZTR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Azitra-Inc.-AZTR&v=1772584893853 "Company Profit Per Employee (in thousands of dollars) Chart Azitra Inc. (AZTR)")
Profit per employee (in thousands of dollars) in the market segment - Pharma skin
Azitra, Inc. is a biotechnology company developing skin microbiome-based treatments for skin diseases. In this innovative field of dermatology, productivity per employee reflects scientific potential. The graph shows the financial return per team, which is an indicator of progress towards the development of new treatments.
%20in%20the%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-skin&v=1772584893873 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma skin")
Profit per employee (in thousands of dollars) for the market as a whole
Azitra is a biotech company focused on dermatology. They use "friendly" bacteria (the microbiome) to treat skin conditions such as eczema. This is an R&D business. This graph, showing average market efficiency, provides context for evaluating the biotech model: all value is created through intellectual labor.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772584893898 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Azitra Inc. (AZTR)
Azitra, Inc. is a biotech company using the skin microbiome to treat skin conditions. There is no revenue per employee during the research phase. The graph is important as an indicator of the future: a successful product could create a new category in dermatology and lead to explosive growth.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Azitra-Inc.-AZTR&v=1772584893922 "Sales chart per company employee Azitra Inc. (AZTR)")
Sales per employee in the market segment - Pharma skin
Azitra (AZTR) is a clinical-stage biotech focused on dermatology. They are developing "living" drugs (based on the skin microbiome) for the treatment of skin diseases. They have no commercial revenue. This chart, showing the average revenue in the sector, serves as a barometer of Azitra's R&D staffing efficiency.
Sales per employee for the market as a whole
Azitra (AZTR) is a clinical-stage biotech company developing living microbiome-based drugs for the treatment of skin diseases. Currently, the company has no commercial revenue. This chart reflects their focus on R&D.
Short shares by company, segment and market as a whole
Shares shorted by company Azitra Inc. (AZTR)
Azitra (AZTR) is a clinical-stage biotech company using "good" bacteria (the microbiome) to treat skin conditions. This chart shows the volume of bearish bets. The shorts reflect a bet that this new scientific approach will not prove effective in rigorous clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Azitra-Inc.-AZTR&v=1772584894044 "Short Shares Chart for the Company Azitra Inc. (AZTR)")
Shares shorted by market segment - Pharma skin
Azitra (AZTR) is a biotech company specializing in dermatology. They use "good" bacteria (the microbiome) to treat skin conditions such as rashes. This chart aggregates short positions in the biotech (dermatology) sector. It reflects investor skepticism about the risks of clinical trials.
Shares shorted by the overall market
Azitra is an early-stage biotech developing skin microbiome-based therapies. Their valuation is a promise of future breakthroughs. This chart measures the overall level of fear. When pessimism dominates the market, investors are reluctant to fund "research projects." They sell off AZTR shares, fearing the company will run out of cash before it can prove its hypothesis.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Azitra Inc. (AZTR)
This chart measures the binary bets on Azitra, a biotech company treating skin conditions (eczema) using microbiome engineering. In this sector, data is king. The publication of positive clinical trial results demonstrating efficacy triggers euphoria and "overheating" (above 70). Any hint of trial failure or FDA delay immediately crashes the oscillator.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Azitra-Inc.-AZTR&v=1772584894188 "RSI 14 indicator chart for the company's stock Azitra Inc. (AZTR)")
RSI 14 Market Segment - Pharma skin
Azitra is a biotech company with a unique approach to dermatology. They are developing treatments for skin conditions (such as eczema) based on microbiome engineering, or "good" bacteria. This chart reflects the overall sentiment in the pharmaceutical sector. It helps assess whether the biotech segment as a whole is overheated, which is important for assessing the value of such an innovative yet speculative company.
RSI 14 for the overall market
Azitra (AZTR), a biotech R&D company, is critically dependent on sentiment, as this chart shows. Market euphoria means open capital markets, making it easy to fund expensive clinical trials in dermatology. In moments of market panic, investors flee unprofitable biotechs, and cash-burning companies risk running out of money.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AZTR (Azitra Inc.)
Azitra is a biotech company developing live (microbiome-based) therapies for dermatological conditions such as eczema. This chart shows the speculative average 12-month price target from analysts, which is almost entirely based on their valuation of this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AZTR-Azitra-Inc.&v=1772584894354 "A chart showing analyst consensus forecasts for the expected stock price. AZTR (Azitra Inc.)")
The difference between the consensus estimate and the actual stock price AZTR (Azitra Inc.)
Azitra is a biotech company that uses "good" bacteria (the skin microbiome) to develop treatments for dermatological conditions such as eczema. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their faith in this innovative R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AZTR-Azitra-Inc.&v=1772584894390 "A chart showing the difference between the consensus forecast and the actual stock price. AZTR (Azitra Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma skin
Azitra is a biotech company developing "skin probiotics." The company uses genetically engineered bacteria to treat skin conditions such as eczema. This chart reflects analysts' overall expectations for the entire skin pharma sector, demonstrating whether experts believe in this vibrant R&D platform.
Analysts' consensus forecast for the overall market share price
Azitra is a biotech company specializing in developing microbiome-based (beneficial bacteria) treatments for skin diseases. This chart shows the overall market appetite. For AZTR, a clinical-stage company, overall market optimism (as shown by the rising chart) is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Azitra Inc.
Azitra is living dermatology. It's a biotech company that uses genetically engineered bacteria (microbiome) to treat skin conditions (eczema, skin cancer). This chart is purely an indicator of their R&D. It doesn't reflect revenue, but rather a speculative assessment of their scientific progress and the market's confidence in their microbiome approach.
AKIMA Market Segment Index - Pharma skin
Azitra, Inc. is a biotech company with a unique approach to treating skin conditions. They harness good bacteria (the microbiome) to combat skin problems. This chart compares their composite index to the sector, demonstrating how this cutting-edge scientific approach stands out from traditional dermatology.
The AKIM Index for the overall market
Azitra is a biopharmaceutical company developing treatments for skin diseases (ichthyosis, Netherton syndrome) using the skin microbiome. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this dermatological research story compares to overall economic trends.
